論文

(5) 癌関連(cancer)

MicroRNA-8073: Tumor suppressor and potential therapeutic treatment.
Mizoguchi A1, Takayama A1, Arai T1, Kawauchi J1, Sudo H1.
PLoS One. 2018 Dec 27;13(12):e0209750. doi: 10.1371/journal.pone.0209750. eCollection 2018.
https://www.ncbi.nlm.nih.gov/pubmed/30589909

Circulating miRNA Panels for Specific and Early Detection in Bladder Cancer.
Usuba W, Urabe F, Yamamoto Y, Matsuzaki J, Sasaki H, Ichikawa M, Takizawa S, Aoki Y, Niida S, Kato K, Egawa S, Chikaraishi T, Fujimoto H, Ochiya T.
Cancer Sci. 2018 Nov 1.
https://www.ncbi.nlm.nih.gov/pubmed/30382619

Expression profile of miR-17/92 cluster is predictive of treatment response in rectal cancer.
Kral J, Korenkova V, Novosadova V, Langerova L, Schneiderova M, Liska V, Levy M, Veskrnova V, Spicak J, Opattova A, Jiraskova K, Vymetalkova V, Vodicka P, Slyskova J.
Carcinogenesis. 2018 Oct 1. doi: 10.1093/carcin/bgy100
https://www.ncbi.nlm.nih.gov/pubmed/30277504

A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder.
Inamoto T1, Uehara H1, Akao Y2, Ibuki N1, Komura K1, Takahara K1, Takai T1, Uchimoto T1, Saito K1, Tanda N1, Yoshikawa Y1, Minami K1, Hirano H1, Nomi H1, Kato R3, Hayashi T3, Azuma H1.
Dis Markers. 2018 Jun 20;2018:5468672. doi: 10.1155/2018/5468672. eCollection 2018
https://www.ncbi.nlm.nih.gov/pubmed/30026881

Integrated extracellular microRNA profiling for ovarian cancer screening.
Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda S, Sonoda T, Kawauchi J, Takizawa S, Aoki Y, Niida S, Sakamoto H, Kato K, Kato T, Ochiya T.
Nat Commun. 2018 Oct 17;9(1):4319. doi: 10.1038/s41467-018-06434-4.
https://www.ncbi.nlm.nih.gov/pubmed/30333487

Circulating microRNAs as potential biomarkers to detect transformation of Barrett's oesophagus to oesophageal adenocarcinoma.
Matsuzaki J1, Suzuki H.
BMJ Open Gastroenterol. 2017 Sep 8;4(1):e000160.
https://www.ncbi.nlm.nih.gov/pubmed/29177063

Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer.
Imamura T, Komatsu S, Ichikawa D, Miyamae M, Okajima W, Ohashi T, Kiuchi J, Nishibeppu K, Konishi H, Shiozaki A, Morimura R, Ikoma H, Ochiai T, Okamoto K, Taniguchi H, Otsuji E.
Sci Rep. 2017 Jul 18;7(1):5708
https://www.ncbi.nlm.nih.gov/pubmed/28720759

Cluster microRNAs miR-194 and miR-215 suppress the tumorigenicity of intestinal tumor organoids.
Nakaoka T, Saito Y, Shimamoto Y, Muramatsu T, Kimura M, Kanai Y, Saito H.
Cancer Sci. 2017 Jan 16
https://www.ncbi.nlm.nih.gov/pubmed/28092415

Amigo2-upregulation in Tumour Cells Facilitates Their Attachment to Liver Endothelial Cells Resulting in Liver Metastases.
Kanda Y, Osaki M, Onuma K, Sonoda A, Kobayashi M, Hamada J, Nicolson GL, Ochiya T, Okada F.
Sci Rep. 2017 Mar 8;7:43567.
https://www.ncbi.nlm.nih.gov/pubmed/28272394

The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo.
Fujihara S, Morishita A, Ogawa K, Tadokoro T, Chiyo T, Kato K, Kobara H, Mori H, Iwama H, Masaki T.
Oncotarget. 2017 Jan 31;8(5):8536-8549.
https://www.ncbi.nlm.nih.gov/pubmed/28052030

Repression of microRNA Function Mediates Inflammation-associated Colon Tumorigenesis.
Yoshikawa T, Wu J, Otsuka M, Kishikawa T, Suzuki N, Takata A, Ohno M, Ishibashi R, Yamagami M, Nakagawa R, Kato N, Miyazawa M, Han J, Koike K.
Gastroenterology. 2016 Nov 5. pii: S0016-5085(16)35322-7
https://www.ncbi.nlm.nih.gov/pubmed/27825961

microRNA-mediated resistance to hypoglycemia in the HepG2 human hepatoma cell line.
microRNA-mediated resistance to hypoglycemia in the HepG2 human hepatoma cell line.
BMC Cancer. 2016 Sep 15;16(1):732.
https://www.ncbi.nlm.nih.gov/pubmed/27629773

Circulating miR-223 in Oral Cancer: Its Potential as a Novel Diagnostic Biomarker and Therapeutic Target.
Tachibana H, Sho R, Takeda Y, Zhang X, Yoshida Y, Narimatsu H, Otani K, Ishikawa S, Fukao A, Asao H, Iino M.
PLoS One. 2016 Jul 21;11(7):e0159693.
https://www.ncbi.nlm.nih.gov/pubmed/27441818

Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320-Mediated Suppression of the Androgen Receptor.
Sato S, Katsushima K, Shinjo K, Hatanaka A, Ohka F, Suzuki S, Naiki-Ito A, Soga N, Takahashi S, Kondo Y.
Cancer Res. 2016 Jul 15;76(14):4192-204.
https://www.ncbi.nlm.nih.gov/pubmed/27216188

Extracellular vesicle miR-7977 is involved in hematopoietic dysfunction of mesenchymal stromal cells via poly(rC) binding protein 1 reduction in myeloid neoplasms.
Horiguchi H, Kobune M, Kikuchi S, Yoshida M, Murata M, Murase K, Iyama S, Takada K, Sato T, Ono K, Hashimoto A, Tatekoshi A, Kamihara Y, Kawano Y, Miyanishi K, Sawada N, Kato J.
Haematologica. 2016 Apr;101(4):437-47
http://www.ncbi.nlm.nih.gov/pubmed/26802051

Novel combination of serum microRNA for detecting breast cancer in the early stage.
Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J, Ono M, Takeshita F, Niida S, Shimizu C, Fujiwara Y, Kinoshita T, Tamura K, Ochiya T.
Cancer Sci. 2016 Mar;107(3):326-34.
http://www.ncbi.nlm.nih.gov/pubmed/26749252

The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin.
Oncol Rep. 2016 Mar;35(3):1582-92.
Kato K, Iwama H, Yamashita T, Kobayashi K, Fujihara S, Fujimori T, Kamada H, Kobara H, Masaki T.
https://www.ncbi.nlm.nih.gov/pubmed/26708419

Microarray Technology and Its Applications for Detecting Plasma microRNA Biomarkers in Digestive Tract Cancers.
Konishi H, Ichikawa D, Arita T, Otsuji E.
Methods Mol Biol. 2016;1368:99-109.
http://www.ncbi.nlm.nih.gov/pubmed/26614071

Antitumor effect of metformin on cholangiocarcinoma: In vitro and in vivo studies.
Oncol Rep. 2015 Dec;34(6):2987-96.
Fujimori T, Kato K, Fujihara S, Iwama H, Yamashita T, Kobayashi K, Kamada H, Morishita A, Kobara H, Mori H, Okano K, Suzuki Y, Masaki T.
https://www.ncbi.nlm.nih.gov/pubmed/26398221

Differences in miRNA expression profiles between GIST and leiomyoma in human samples acquired by submucosal tunneling biopsy.
Fujita K, Kobara H, Mori H, Fujihara S, Chiyo T, Matsunaga T, Nishiyama N, Ayaki M, Yachida T, Morishita A, Fujiwara M, Okano K, Suzuki Y, Iwama H, Masaki T.
Endosc Int Open. 2015 Dec;3(6):E665-71
http://www.ncbi.nlm.nih.gov/pubmed/26716134

Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer.
Miyamae M, Komatsu S, Ichikawa D, Kawaguchi T, Hirajima S, Okajima W, Ohashi T, Imamura T, Konishi H, Shiozaki A, Morimura R, Ikoma H, Ochiai T, Okamoto K, Taniguchi H, Otsuji E.
Br J Cancer. 2015 Nov 17;113(10):1467-76.
http://www.ncbi.nlm.nih.gov/pubmed/26505678

Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays.
Ono S, Lam S, Nagahara M, Hoon DS.
J Clin Med. 2015 Oct 23;4(10):1890-907.
http://www.ncbi.nlm.nih.gov/pubmed/26512704

Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest.
Kobayashi K, Morishita A, Iwama H, Fujita K, Okura R, Fujihara S, Yamashita T, Fujimori T, Kato K, Kamada H, Niki T, Hirashima M, Okano K, Suzuki Y, Masaki T.
Oncol Rep. 2015 Oct;34(4):1761-70.
https://www.ncbi.nlm.nih.gov/pubmed/26260906

Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo.
Fujita K, Iwama H, Sakamoto T, Okura R, Kobayashi K, Takano J, Katsura A, Tatsuta M, Maeda E, Mimura S, Nomura T, Tani J, Miyoshi H, Morishita A, Yoneyama H, Yamana Y, Himoto T, Okano K, Suzuki Y, Niki T, Hirashima M, Masaki T.
Int J Oncol. 2015;46(6):2419-30.
https://www.ncbi.nlm.nih.gov/pubmed/25823465

SUV420H2 suppresses breast cancer cell invasion through down regulation of the SH2 domain-containing focal adhesion protein tensin-3.
Shinchi Y, Hieda M, Nishioka Y, Matsumoto A, Yokoyama Y, Kimura H, Matsuura S, Matsuura N.
Exp Cell Res. 2015 May 15;334(1):90-9.
http://www.ncbi.nlm.nih.gov/pubmed/25814362

Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells.
Yamashita R, Sato M, Kakumu T, Hase T, Yogo N, Maruyama E, Sekido Y, Kondo M, Hasegawa Y.
Cancer Med. 2015 Apr;4(4):551-64.
http://www.ncbi.nlm.nih.gov/pubmed/25641933

Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer.
Hiraki M, Nishimura J, Takahashi H, Wu X, Takahashi Y, Miyo M, Nishida N, Uemura M, Hata T, Takemasa I, Mizushima T, Soh JW, Doki Y, Mori M, Yamamoto H.
Mol Ther Nucleic Acids. 2015 Mar 10;4:e231.
http://www.ncbi.nlm.nih.gov/pubmed/25756961

Clustered MicroRNAs of the Epstein-Barr Virus Cooperatively Downregulate an Epithelial Cell-Specific Metastasis Suppressor.
Kanda T, Miyata M, Kano M, Kondo S, Yoshizaki T, Iizasa H.
J Virol. 2015 Mar 1;89(5):2684-97.
http://www.ncbi.nlm.nih.gov/pubmed/25520514

MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers.
Kojima M, Sudo H, Kawauchi J, Takizawa S, Kondou S, Nobumasa H, Ochiai A.
PLoS One. 2015 Feb 23;10(2):e0118220.
http://www.ncbi.nlm.nih.gov/pubmed/25706130

Contextual niche signals towards colorectal tumor progression by mesenchymal stem cell in the mouse xenograft model.
Nakagaki S, Arimura Y, Nagaishi K, Isshiki H, Nasuno M, Watanabe S, Idogawa M, Yamashita K, Naishiro Y, Adachi Y, Suzuki H, Fujimiya M, Imai K, Shinomura Y.
J Gastroenterol. 2015 Feb 14.
http://www.ncbi.nlm.nih.gov/pubmed/25680886

Tropomodulin 1 Expression Driven by NF-κB Enhances Breast Cancer Growth.
Ito-Kureha T, Koshikawa N, Yamamoto M, Semba K, Yamaguchi N, Yamamoto T, Seiki M, Inoue J.
Cancer Res. 2015 Jan 1;75(1):62-72.
http://www.ncbi.nlm.nih.gov/pubmed/25398440

Involvement of miR-518c-5p to growth and metastasis in oral cancer.
Kinouchi M, Uchida D, Kuribayashi N, Tamatani T1, Nagai H, Miyamoto Y. 
PLoS One. 2014 Dec 23;9(12):e115936.
http://www.ncbi.nlm.nih.gov/pubmed/25536052

Plasma microRNA profiles: identification of miR-25 as a novel diagnostic and monitoring biomarker in oesophageal squamous cell carcinoma.
Komatsu S, Ichikawa D, Hirajima S, Kawaguchi T, Miyamae M, Okajima W, Ohashi T, Arita T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Yagi N, Otsuji E.
Br J Cancer. 2014 Oct 14;111(8):1614-24.
http://www.ncbi.nlm.nih.gov/pubmed/25117812

MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer.
Hasegawa S, Eguchi H, Nagano H, Konno M, Tomimaru Y, Wada H, Hama N, Kawamoto K, Kobayashi S, Nishida N, Koseki J, Nishimura T, Gotoh N, Ohno S, Yabuta N, Nojima H, Mori M, Doki Y, Ishii H.
Br J Cancer. 2014 Oct 14;111(8):1572-80.
http://www.ncbi.nlm.nih.gov/pubmed/25117811

Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis.
Takaki Y, Saito Y, Takasugi A, Toshimitsu K, Yamada S, Muramatsu T, Kimura M, Sugiyama K, Suzuki H, Arai E, Ojima H, Kanai Y, Saito H.
Cancer Sci. 2014 Oct;105(10):1254-60.
http://www.ncbi.nlm.nih.gov/pubmed/25117675

Guanine nucleotide-binding protein 1 is one of the key molecules contributing to cancer cell radioresistance.
Fukumoto M, Amanuma T, Kuwahara Y, Shimura T, Suzuki M, Mori S, Kumamoto H, Saito Y, Ohkubo Y, Duan Z, Sano K, Oguchi T, Kainuma K, Usami S, Kinoshita K, Lee I, Fukumoto M.
Cancer Sci. 2014 Oct;105(10):1351-9.
http://www.ncbi.nlm.nih.gov/pubmed/25098609

Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells.
Ono M, Kosaka N, Tominaga N, Yoshioka Y, Takeshita F, Takahashi RU, Yoshida M, Tsuda H, Tamura K, Ochiya T.
Sci Signal. 2014 Jul 1;7(332)
http://www.ncbi.nlm.nih.gov/pubmed/24985346

MicroRNA-203 inhibits the progression of esophageal squamous cell carcinoma with restored epithelial tissue architecture in vivo.
Okumura T, Shimada Y, Moriyama M, Takei Y, Omura T, Sekine S, Nagata T, Shimizu K, Tsukada K.
Int J Oncol. 2014 Jun;44(6):1923-32.
http://www.ncbi.nlm.nih.gov/pubmed/24692008

Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells.
Hibino S, Saito Y, Muramatsu T, Otani A, Kasai Y, Kimura M, Saito H.
Oncogenesis. 2014 May 26;3:e104.
http://www.ncbi.nlm.nih.gov/pubmed/24861464

Identification of signaling pathways modulated by RHBDD2 in breast cancer cells: a link to the unfolded protein response.
Lacunza E, Rabassa ME, Canzoneri R, Pellon-Maison M, Croce MV, Aldaz CM, Abba MC.
Cell Stress Chaperones. 2014 May;19(3):379-88.
http://www.ncbi.nlm.nih.gov/pubmed/24078384

CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells.
Komiya E, Ohnuma K, Yamazaki H, Hatano R1, Iwata S, Okamoto T, Dang NH, Yamada T, Morimoto C.
Biochem Biophys Res Commun. 2014 May 16;447(4):609-15.
http://www.ncbi.nlm.nih.gov/pubmed/24747072

Matrix metalloproteinase (MMP)-9 in cancer-associated fibroblasts (CAFs) is suppressed by omega-3 polyunsaturated fatty acids in vitro and in vivo.
Taguchi A, Kawana K, Tomio K, Yamashita A, Isobe Y, Nagasaka K, Koga K, Inoue T, Nishida H, Kojima S, Adachi K, Matsumoto Y, Arimoto T, Wada-Hiraike O, Oda K, Kang JX, Arai H, Arita M, Osuga Y, Fujii T.
PLoS One. 2014 Feb 27;9(2):e89605.
http://www.ncbi.nlm.nih.gov/pubmed/24586907

Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy.
Omura T, Shimada Y, Nagata T, Okumura T, Fukuoka J, Yamagishi F, Tajika S, Nakajima S, Kawabe A, Tsukada K.
Oncol Rep. 2014 Feb;31(2):613-8.
http://www.ncbi.nlm.nih.gov/pubmed/24317477

Gene expression analysis using a highly sensitive DNA microarray for colorectal cancer screening.
Koga Y, Yamazaki N, Takizawa S, Kawauchi J, Nomura O, Yamamoto S, Saito N, Kakugawa Y, Otake Y, Matsumoto M, Matsumura Y.
Anticancer Res. 2014 Jan;34(1):169-76.
http://www.ncbi.nlm.nih.gov/pubmed/24403458

Role of aquaporin-5 in gallbladder carcinoma.
Sekine S, Shimada Y, Nagata T, Sawada S, Yoshioka I, Matsui K, Moriyama M, Omura T, Osawa S, Shibuya K, Hashimoto I, Watanabe T, Hojo S, Hori R, Okumura T, Yoshida T, Tsukada K.
Eur Surg Res. 2013;51(3-4):108-17.
http://www.ncbi.nlm.nih.gov/pubmed/24217644

Differential gene expression in cholesteatoma by DNA chip analysis.
Macias JD, Gerkin RD, Locke D, Macias MP.
Laryngoscope. 2013 Oct;123 Suppl S5:S1-21.
http://www.ncbi.nlm.nih.gov/pubmed/23670528

Gene expression of bone morphogenic protein 8B in the primary site, peripheral blood and bone marrow of patients with gastric cancer.
Mima K, Fukagawa T, Kurashige J, Takano Y, Uchi R, Ueo H, Matsumura T, Ishibashi M, Sawada G, Takahashi Y, Akiyoshi S, Eguchi H, Sudo T, Sugimachi K, Watanabe M, Ishii H, Mori M, Baba H, Sasako M, Mimori K.
Oncol Lett. 2013 Aug;6(2):387-392.
http://www.ncbi.nlm.nih.gov/pubmed/24137334

MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells.
Qu Y, Li WC, Hellem MR, Rostad K, Popa M, McCormack E, Oyan AM, Kalland KH, Ke XS.
Int J Cancer. 2013 Aug 1;133(3):544-55.
http://www.ncbi.nlm.nih.gov/pubmed/23354685

Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant.
Funakoshi-Tago M, Sumi K, Kasahara T, Tago K.
PLoS One. 2013;8(1):e52844.
http://www.ncbi.nlm.nih.gov/pubmed/23300995

MiR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.
Endo Y, Toyama T, Takahashi S, Yoshimoto N, Iwasa M, Asano T, Fujii Y, Yamashita H.
Endocr Relat Cancer. 2013 Feb 18;20(1):91-102.
http://www.ncbi.nlm.nih.gov/pubmed/23183268

Identification of miR-30d as a novel prognostic maker of prostate cancer.
Kobayashi N, Uemura H, Nagahama K, Okudela K, Furuya M, Ino Y, Ito Y, Hirano H, Inayama Y, Aoki I, Nagashima Y, Kubota Y, Ishiguro H.
Oncotarget. 2012 Nov;3(11):1455-71.
http://www.ncbi.nlm.nih.gov/pubmed/23231923

Clinical significance of miR-144-ZFX axis in disseminated tumour cells in bone marrow in gastric cancer cases.
Akiyoshi S, Fukagawa T, Ueo H, Ishibashi M, Takahashi Y, Fabbri M, Sasako M, Maehara Y, Mimori K, Mori M.
Br J Cancer. 2012 Oct 9;107(8):1345-53.
http://www.ncbi.nlm.nih.gov/pubmed/22955854

High-Throughput MicroRNA (miRNAs) Arrays Unravel the Prognostic Role of MiR-211 in Pancreatic Cancer.
Giovannetti E, van der Velde A, Funel N, Vasile E, Perrone V, Leon LG, De Lio N, Avan A, Caponi S, Pollina LE, Gallá V, Sudo H, Falcone A, Campani D, Boggi U, Peters GJ.
PLoS One. 2012;7(11):e49145.
http://www.ncbi.nlm.nih.gov/pubmed/23155457

Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells.
Ichikawa T, Sato F, Terasawa K, Tsuchiya S, Toi M, Tsujimoto G, Shimizu K.
PLoS One. 2012;7(2):e31422.
http://www.ncbi.nlm.nih.gov/pubmed/22384020

Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells.
Horio M, Sato M, Takeyama Y, Elshazley M, Yamashita R, Hase T, Yoshida K, Usami N, Yokoi K, Sekido Y, Kondo M, Toyokuni S, Gazdar AF, Minna JD, Hasegawa Y.
Ann Surg Oncol. 2012 Jul;19 Suppl 3:S634-45.
http://www.ncbi.nlm.nih.gov/pubmed/22086445

The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo.
Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, Kobara H, Mori H, Himoto T, Okano K, Suzuki Y, Murao K, Masaki T.
Mol Cancer Ther. 2012 Mar;11(3):549-60. 
http://www.ncbi.nlm.nih.gov/pubmed/22222629

Fibroblast growth factor-2 is an important factor that maintains cellular immaturity and contributes to aggressiveness of osteosarcoma.
Shimizu T, Ishikawa T, Iwai S, Ueki A, Sugihara E, Onishi N, Kuninaka S, Miyamoto T, Toyama Y, Ijiri H, Mori H, Matsuzaki Y, Yaguchi T, Nishio H, Kawakami Y, Ikeda Y, Saya H.
Mol Cancer Res. 2012 Mar;10(3):454-68. 
http://www.ncbi.nlm.nih.gov/pubmed/22228819

Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma.
Konishi H, Ichikawa D, Komatsu S, Shiozaki A, Tsujiura M, Takeshita H, Morimura R, Nagata H, Arita T, Kawaguchi T, Hirashima S, Fujiwara H, Okamoto K, Otsuji E.
Br J Cancer. 2012 Feb 14;106(4):740-7.
http://www.ncbi.nlm.nih.gov/pubmed/22262318

DNA damage signaling triggers degradation of histone methyltransferases through APC/C(Cdh1) in senescent cells.
Takahashi A, Imai Y, Yamakoshi K, Kuninaka S, Ohtani N, Yoshimoto S, Hori S, Tachibana M, Anderton E, Takeuchi T, Shinkai Y, Peters G, Saya H, Hara E.
Mol Cell. 2012 Jan 13;45(1):123-31. 
http://www.ncbi.nlm.nih.gov/pubmed/22178396

MicroRNA profiling of gastric cancer patients from formalin-fixed paraffin-embedded samples.
Osawa S, Shimada Y, Sekine S, Okumura T, Nagata T, Fukuoka J, Tsukada K.
Oncol Lett. 2011 Jul;2(4):613-619.
http://www.ncbi.nlm.nih.gov/pubmed/22848236

miR-22 represses cancer progression by inducing cellular senescence.
Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, Matsunaga J, Takahashi RU, Takata T, Shimamoto A, Ochiya T, Tahara H.
J Cell Biol. 2011 Apr 18;193(2):409-24.
http://www.ncbi.nlm.nih.gov/pubmed/21502362

Identification of altered MicroRNA expression patterns in synovial sarcoma.
Hisaoka M, Matsuyama A, Nagao Y, Luan L, Kuroda T, Akiyama H, Kondo S, Hashimoto H.
Genes Chromosomes Cancer. 2011 Mar;50(3):137-45.
http://www.ncbi.nlm.nih.gov/pubmed/21213367

MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria.
Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, Takizawa S, Tsuchiya S, Tsujimoto G, Uemoto S, Shimizu K.
PLoS One. 2011 Jan 27;6(1):e16435.
http://www.ncbi.nlm.nih.gov/pubmed/21298008

MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1).
Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y, Shimizu K, Tsujimoto G.
J Biol Chem. 2011 Jan 7;286(1):420-8.
http://www.ncbi.nlm.nih.gov/pubmed/21044961

Circadian disruption accelerates tumor growth and angio/stromagenesis through a Wnt signaling pathway.
Yasuniwa Y, Izumi H, Wang KY, Shimajiri S, Sasaguri Y, Kawai K, Kasai H, Shimada T, Miyake K, Kashiwagi E, Hirano G, Kidani A, Akiyama M, Han B, Wu Y, Ieiri I, Higuchi S, Kohno K.
PLoS One. 2010 Dec 23;5(12):e15330.
http://www.ncbi.nlm.nih.gov/pubmed/21203463

c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis.
Shimizu T, Ishikawa T, Sugihara E, Kuninaka S, Miyamoto T, Mabuchi Y, Matsuzaki Y, Tsunoda T, Miya F, Morioka H, Nakayama R, Kobayashi E, Toyama Y, Kawai A, Ichikawa H, Hasegawa T, Okada S, Ito T, Ikeda Y, Suda T, Saya H.
Oncogene. 2010 Oct 21;29(42):5687-99. 
http://www.ncbi.nlm.nih.gov/pubmed/20676132

Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model.
Kitamura T, Fujishita T, Loetscher P, Revesz L, Hashida H, Kizaka-Kondoh S, Aoki M, Taketo MM.
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13063-8
http://www.ncbi.nlm.nih.gov/pubmed/20616008

Clinical application of cytokine-related gene polymorphism analysis using a newly developed DNA chip in critically ill patients.
Otani S, Oda S, Sadahiro T, Nakamura M, Watanabe E, Nakada TA, Abe R, Tokuhisa T, Hirasawa H.
Clin Biochem. 2009 Sep;42(13-14):1387-93. 
http://www.ncbi.nlm.nih.gov/pubmed/19527699

cDNA microarray analysis of esophageal cancer: discoveries and prospects.
Shimada Y, Sato F, Shimizu K, Tsujimoto G, Tsukada K.
Gen Thorac Cardiovasc Surg. 2009 Jul;57(7):347-56. 
http://www.ncbi.nlm.nih.gov/pubmed/19597924